IMPEDIMED LIMITED - Announcements

2.22%

4.4¢

Market Cap $89.31M

Technology Scientific & Technical Instruments

ImpediMed Limited is an Australia-based medical technology company. The Company uses... ImpediMed Limited is an Australia-based medical technology company. The Company uses bioimpedance spectroscopy (BIS) technology to generate data to maximize patient health. The Company designs and manufactures medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status and tissue composition. The Company’s SOZO Digital Health Platform is a Food and Drug Administration (FDA)-cleared bioimpedance spectroscopy (BIS) solution for the clinical assessment of lymphedema. SOZO uses its BIS technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. Its product SFB7 measures fluid status and tissue composition for clinical and research applications. Its ImpediVET is a single-channel, tetrapolar bioimpedance spectroscopy (BIS) device that measures fluid status and tissue composition for veterinary applications.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

IPD	Quarterly Activities Report and Appendix 4C - Jun-2025 Qtr	PRICE SENSITIVE	31/07/25	1.13MB	Share
IPD	Q4 FY25 sales and growth capital facility update	PRICE SENSITIVE	16/07/25	428.93KB	Share
IPD	Quarterly Activities Report and Appendix 4C - Mar-2025 Qtr	PRICE SENSITIVE	30/04/25	1.13MB	Share
IPD	S&P DJI Announces March 2025 Quarterly Rebalance	PRICE SENSITIVE	07/03/25	174.42KB	Share
IPD	Appendix 4D and Interim Financial Report	PRICE SENSITIVE	26/02/25	930.39KB	Share
IPD	ImpediMed secures US$15 million growth capital facility	PRICE SENSITIVE	06/02/25	352.12KB	Share
IPD	Quarterly Activities Report and Appendix 4C - Dec-2024 Qtr	PRICE SENSITIVE	31/01/25	1.12MB	Share
IPD	Presentation - Bell Potter Conference	PRICE SENSITIVE	18/11/24	954.38KB	Share
IPD	Investor Presentation	PRICE SENSITIVE	22/10/24	790.28KB	Share
IPD	Quarterly Activities Report and Appendix 4C - Sep-2024 Qtr	PRICE SENSITIVE	22/10/24	1.13MB	Share
IPD	Positive coverage published by two additional payors	PRICE SENSITIVE	24/09/24	313.74KB	Share
IPD	HealthInvest Presentation	PRICE SENSITIVE	18/09/24	503.51KB	Share
IPD	Investor Presentation	PRICE SENSITIVE	29/08/24	909.92KB	Share
IPD	FY2024 Results	PRICE SENSITIVE	29/08/24	156.22KB	Share
IPD	Appendix 4E	PRICE SENSITIVE	29/08/24	345.13KB	Share
IPD	Investor Presentation	PRICE SENSITIVE	29/07/24	1.7MB	Share
IPD	Quarterly Activities Report and Appendix 4C - Jun-2024 Qtr	PRICE SENSITIVE	29/07/24	1.15MB	Share
IPD	Appointment of CEO and CF&OO	PRICE SENSITIVE	22/07/24	315.66KB	Share
IPD	Investor Presentation	PRICE SENSITIVE	30/04/24	2.61MB	Share
IPD	Quarterly Activities Report and Appendix 4C - March-2024 Qtr	PRICE SENSITIVE	30/04/24	1.14MB	Share
IPD	Organisational Changes	PRICE SENSITIVE	17/04/24	330.12KB	Share
IPD	S&P DJI Announces March 2024 Quarterly Rebalance	PRICE SENSITIVE	01/03/24	120.24KB	Share
IPD	Investor Presentation	PRICE SENSITIVE	27/02/24	2.15MB	Share
IPD	ImpediMed 2024 Half-Year Financial Results	PRICE SENSITIVE	27/02/24	524.51KB	Share
IPD	Appendix 4D and Interim Financial Report	PRICE SENSITIVE	27/02/24	587.44KB	Share
IPD	Quarterly Activities Report and Appendix 4C - Dec-23 Qtr	PRICE SENSITIVE	31/01/24	1.27MB	Share
IPD	ImpediMed announces leadership and Board changes	PRICE SENSITIVE	20/11/23	142.03KB	Share
IPD	Largest US Private Payor Updates Medical Policy for BIS	PRICE SENSITIVE	03/11/23	103.07KB	Share
IPD	Appendix 4C & Quarterly Activities Report - Sep-23 Qtr	PRICE SENSITIVE	31/10/23	803.43KB	Share
IPD	Appendix 4E	PRICE SENSITIVE	31/08/23	334.45KB	Share
IPD	APPENDIX 4C - Quarterly Activities Report	PRICE SENSITIVE	24/07/23	1.02MB	Share
IPD	First Top 5 National Payor Covering SOZO Testing	PRICE SENSITIVE	19/07/23	196.86KB	Share
IPD	ImpediMed Achieves Critical Mass in First Key Target State	PRICE SENSITIVE	29/06/23	163.2KB	Share
IPD	SPP Results	PRICE SENSITIVE	21/06/23	400.62KB	Share
IPD	ImpediMed Announces Third Medical Policy Covering SOZO	PRICE SENSITIVE	20/06/23	348.07KB	Share
IPD	First Published Medical Policy from Blue Cross Blue Shield	PRICE SENSITIVE	05/06/23	351.24KB	Share
IPD	Share Purchase Plan Opens	PRICE SENSITIVE	30/05/23	354.81KB	Share
IPD	First Published Medical Policy for Bioimedance Spectroscopy	PRICE SENSITIVE	25/05/23	328.16KB	Share
IPD	Capital Raising Investor Presentation	PRICE SENSITIVE	19/05/23	1.86MB	Share
IPD	Placement and SPP Notification	PRICE SENSITIVE	19/05/23	344.43KB	Share
IPD	Trading Halt	PRICE SENSITIVE	18/05/23	279.19KB	Share
IPD	SOZO Pro Achieves Clearance by U.S. FDA	PRICE SENSITIVE	05/05/23	141.37KB	Share
IPD	Appendix 4C & Quarterly Activities Report - Mar-23 Qtr	PRICE SENSITIVE	17/04/23	1.18MB	Share
IPD	NCCN Guidelines Now Recommend Bioimpedance Spectroscopy	PRICE SENSITIVE	27/03/23	160.99KB	Share
IPD	S&P DJI Announces March 2023 Quarterly Rebalance	PRICE SENSITIVE	03/03/23	128.97KB	Share
IPD	Appendix 4D and Interim Financial Report	PRICE SENSITIVE	24/02/23	6.56MB	Share
IPD	Appendix 4C & Quarterly Activities Report - Dec-22 Qtr	PRICE SENSITIVE	30/01/23	862.89KB	Share
IPD	New Version of NCCN Guidelines for Breast Cancer	PRICE SENSITIVE	30/01/23	265.45KB	Share
IPD	ImpediMed Announces Appointment of Managing Director and CEO	PRICE SENSITIVE	29/11/22	223.25KB	Share
IPD	ImpediMed Announces Management Reorganisation	PRICE SENSITIVE	22/11/22	277.81KB	Share
IPD	AstraZeneca Further Extends Clinical Trial Contract	PRICE SENSITIVE	09/11/22	266.76KB	Share
IPD	Appendix 4C & Quarterly Activities Report - Sep-22 Qtr	PRICE SENSITIVE	19/10/22	1.44MB	Share
IPD	New Corporate Oncology Account with GenesisCare	PRICE SENSITIVE	04/10/22	91.79KB	Share
IPD	2022 Annual Report & Annual General Meeting Date	PRICE SENSITIVE	29/08/22	5.22MB	Share
IPD	Appendix 4E	PRICE SENSITIVE	29/08/22	193.36KB	Share
IPD	Appendix 4C & Quarterly Activities Report - Jun-2022 Qtr	PRICE SENSITIVE	28/07/22	1.15MB	Share
IPD	ImpediMed CEO Announces Departure	PRICE SENSITIVE	26/07/22	133.66KB	Share
IPD	Lymphoedema Risk Factors Paper Published	PRICE SENSITIVE	11/07/22	253.37KB	Share
IPD	Appendix 4C & Quarterly Activities Report	PRICE SENSITIVE	28/04/22	6.39MB	Share
IPD	AstraZeneca extends and increases Renal Contract	PRICE SENSITIVE	18/03/22	268.95KB	Share
IPD	S&P DJI Announces March 2022 Quarterly Rebalance	PRICE SENSITIVE	04/03/22	175.5KB	Share
IPD	Appendix 4D and Interim Financial Report	PRICE SENSITIVE	25/02/22	2.45MB	Share
IPD	ImpediMed Announces End Stage Renal Disease Trial Agreement	PRICE SENSITIVE	11/02/22	272.39KB	Share
IPD	PREVENT Trial Peer-Reviewed and Published	PRICE SENSITIVE	01/02/22	107.49KB	Share
IPD	Appendix 4C & Quarterly Activities Report	PRICE SENSITIVE	31/01/22	1.37MB	Share
IPD	Share Purchase Plan Successfully Completed	PRICE SENSITIVE	18/11/21	319.82KB	Share
IPD	2021 Annual General Meeting - Chairman's Address	PRICE SENSITIVE	10/11/21	363.62KB	Share
IPD	AGM Presentation - November 2021	PRICE SENSITIVE	10/11/21	11.58MB	Share
IPD	AstraZeneca extends and increases HF & Renal Contract	PRICE SENSITIVE	04/11/21	273.37KB	Share
IPD	Share Purchase Plan Offer Booklet	PRICE SENSITIVE	03/11/21	270.02KB	Share
IPD	ImpediMed's Share Purchase Plan Opens	PRICE SENSITIVE	03/11/21	325.18KB	Share
IPD	Appendix 4C & Quarterly Activities Report	PRICE SENSITIVE	28/10/21	432.8KB	Share
IPD	Capital Raising Presentation	PRICE SENSITIVE	27/10/21	2.4MB	Share
IPD	ImpediMed Completes A$35 Million Institutional Placement	PRICE SENSITIVE	27/10/21	422.8KB	Share
IPD	Trading Halt	PRICE SENSITIVE	25/10/21	278.73KB	Share
IPD	PREVENT Trial Successful, Statistically Significant Results	PRICE SENSITIVE	19/10/21	263.77KB	Share
IPD	Trading Halt	PRICE SENSITIVE	19/10/21	283.73KB	Share
IPD	New Corporate Oncology Account with Icon Group	PRICE SENSITIVE	30/09/21	264.67KB	Share
IPD	SOZO Heart Failure Program Initiated at AdvocateAuroraHealth	PRICE SENSITIVE	27/09/21	257.92KB	Share
IPD	HFSA Abstracts Demonstrate Utility of SOZO for HF Patients	PRICE SENSITIVE	13/09/21	271.69KB	Share
IPD	Appendix 4E	PRICE SENSITIVE	25/08/21	235.99KB	Share
IPD	Receipt of $1.8 Million R&D Tax Incentive Refund	PRICE SENSITIVE	24/08/21	247.96KB	Share
IPD	FDA Grants Breakthrough Device Designation for Renal Failure	PRICE SENSITIVE	23/08/21	277.41KB	Share
IPD	Appendix 4C & Quarterly Activities Report	PRICE SENSITIVE	27/07/21	1.13MB	Share
IPD	Official Release of SOZO Version 4.0 Software	PRICE SENSITIVE	25/05/21	538.51KB	Share
IPD	ACC Abstract Demonstrates Potential of SOZO in Heart Failure	PRICE SENSITIVE	04/05/21	286.59KB	Share
IPD	Appendix 4C - Quarter ended 31 March 2021	PRICE SENSITIVE	28/04/21	1.4MB	Share
IPD	FDA Clearance for SOZO Heart Failure Index	PRICE SENSITIVE	22/04/21	424.71KB	Share
IPD	SOZO Clinical Utility in Heart Failure Published	PRICE SENSITIVE	08/04/21	363.68KB	Share
IPD	Option Exercise and Preliminary Q3 FY21 Cashflow Results	PRICE SENSITIVE	07/04/21	281.79KB	Share
IPD	ImpediMed Achieves Milestone 200,000 SOZO Patient Tests	PRICE SENSITIVE	04/03/21	256.58KB	Share
IPD	Appendix 4D - Half-Year Results Ended 31 December 2020	PRICE SENSITIVE	22/02/21	2.65MB	Share
IPD	American College of Cardiology Accepts SOZO HF Abstract	PRICE SENSITIVE	12/02/21	271.64KB	Share
IPD	Appendix 4C - Quarter ended 31 December 2020	PRICE SENSITIVE	28/01/21	1.09MB	Share
IPD	PREVENT Trial Finishes, Final Patient Completes Follow-up	PRICE SENSITIVE	11/01/21	263.47KB	Share
IPD	Option Exercise and Preliminary Quarterly Cash Flow Results	PRICE SENSITIVE	07/01/21	267.43KB	Share
IPD	Meta-Analysis-BIS L-Dex Statistically Significant Reduction	PRICE SENSITIVE	30/11/20	309.44KB	Share
IPD	ImpediMed Secures First Commercial Heart Failure Sales	PRICE SENSITIVE	18/11/20	280.47KB	Share
IPD	AstraZeneca Selects SOZO for Second Large Renal Trial	PRICE SENSITIVE	09/11/20	268.31KB	Share
IPD	Landmark Radiation Manuscript Supports L-Dex Use	PRICE SENSITIVE	29/10/20	285.73KB	Share

IPD Quarterly Activities Report and Appendix 4C - Jun-2025 Qtr
31/07/25	PRICE SENSITIVE	1.13MB	Share
IPD Q4 FY25 sales and growth capital facility update
16/07/25	PRICE SENSITIVE	428.93KB	Share
IPD Quarterly Activities Report and Appendix 4C - Mar-2025 Qtr
30/04/25	PRICE SENSITIVE	1.13MB	Share
IPD S&P DJI Announces March 2025 Quarterly Rebalance
07/03/25	PRICE SENSITIVE	174.42KB	Share
IPD Appendix 4D and Interim Financial Report
26/02/25	PRICE SENSITIVE	930.39KB	Share
IPD ImpediMed secures US$15 million growth capital facility
06/02/25	PRICE SENSITIVE	352.12KB	Share
IPD Quarterly Activities Report and Appendix 4C - Dec-2024 Qtr
31/01/25	PRICE SENSITIVE	1.12MB	Share
IPD Presentation - Bell Potter Conference
18/11/24	PRICE SENSITIVE	954.38KB	Share
IPD Investor Presentation
22/10/24	PRICE SENSITIVE	790.28KB	Share
IPD Quarterly Activities Report and Appendix 4C - Sep-2024 Qtr
22/10/24	PRICE SENSITIVE	1.13MB	Share
IPD Positive coverage published by two additional payors
24/09/24	PRICE SENSITIVE	313.74KB	Share
IPD HealthInvest Presentation
18/09/24	PRICE SENSITIVE	503.51KB	Share
IPD Investor Presentation
29/08/24	PRICE SENSITIVE	909.92KB	Share
IPD FY2024 Results
29/08/24	PRICE SENSITIVE	156.22KB	Share
IPD Appendix 4E
29/08/24	PRICE SENSITIVE	345.13KB	Share
IPD Investor Presentation
29/07/24	PRICE SENSITIVE	1.7MB	Share
IPD Quarterly Activities Report and Appendix 4C - Jun-2024 Qtr
29/07/24	PRICE SENSITIVE	1.15MB	Share
IPD Appointment of CEO and CF&OO
22/07/24	PRICE SENSITIVE	315.66KB	Share
IPD Investor Presentation
30/04/24	PRICE SENSITIVE	2.61MB	Share
IPD Quarterly Activities Report and Appendix 4C - March-2024 Qtr
30/04/24	PRICE SENSITIVE	1.14MB	Share
IPD Organisational Changes
17/04/24	PRICE SENSITIVE	330.12KB	Share
IPD S&P DJI Announces March 2024 Quarterly Rebalance
01/03/24	PRICE SENSITIVE	120.24KB	Share
IPD Investor Presentation
27/02/24	PRICE SENSITIVE	2.15MB	Share
IPD ImpediMed 2024 Half-Year Financial Results
27/02/24	PRICE SENSITIVE	524.51KB	Share
IPD Appendix 4D and Interim Financial Report
27/02/24	PRICE SENSITIVE	587.44KB	Share
IPD Quarterly Activities Report and Appendix 4C - Dec-23 Qtr
31/01/24	PRICE SENSITIVE	1.27MB	Share
IPD ImpediMed announces leadership and Board changes
20/11/23	PRICE SENSITIVE	142.03KB	Share
IPD Largest US Private Payor Updates Medical Policy for BIS
03/11/23	PRICE SENSITIVE	103.07KB	Share
IPD Appendix 4C & Quarterly Activities Report - Sep-23 Qtr
31/10/23	PRICE SENSITIVE	803.43KB	Share
IPD Appendix 4E
31/08/23	PRICE SENSITIVE	334.45KB	Share
IPD APPENDIX 4C - Quarterly Activities Report
24/07/23	PRICE SENSITIVE	1.02MB	Share
IPD First Top 5 National Payor Covering SOZO Testing
19/07/23	PRICE SENSITIVE	196.86KB	Share
IPD ImpediMed Achieves Critical Mass in First Key Target State
29/06/23	PRICE SENSITIVE	163.2KB	Share
IPD SPP Results
21/06/23	PRICE SENSITIVE	400.62KB	Share
IPD ImpediMed Announces Third Medical Policy Covering SOZO
20/06/23	PRICE SENSITIVE	348.07KB	Share
IPD First Published Medical Policy from Blue Cross Blue Shield
05/06/23	PRICE SENSITIVE	351.24KB	Share
IPD Share Purchase Plan Opens
30/05/23	PRICE SENSITIVE	354.81KB	Share
IPD First Published Medical Policy for Bioimedance Spectroscopy
25/05/23	PRICE SENSITIVE	328.16KB	Share
IPD Capital Raising Investor Presentation
19/05/23	PRICE SENSITIVE	1.86MB	Share
IPD Placement and SPP Notification
19/05/23	PRICE SENSITIVE	344.43KB	Share
IPD Trading Halt
18/05/23	PRICE SENSITIVE	279.19KB	Share
IPD SOZO Pro Achieves Clearance by U.S. FDA
05/05/23	PRICE SENSITIVE	141.37KB	Share
IPD Appendix 4C & Quarterly Activities Report - Mar-23 Qtr
17/04/23	PRICE SENSITIVE	1.18MB	Share
IPD NCCN Guidelines Now Recommend Bioimpedance Spectroscopy
27/03/23	PRICE SENSITIVE	160.99KB	Share
IPD S&P DJI Announces March 2023 Quarterly Rebalance
03/03/23	PRICE SENSITIVE	128.97KB	Share
IPD Appendix 4D and Interim Financial Report
24/02/23	PRICE SENSITIVE	6.56MB	Share
IPD Appendix 4C & Quarterly Activities Report - Dec-22 Qtr
30/01/23	PRICE SENSITIVE	862.89KB	Share
IPD New Version of NCCN Guidelines for Breast Cancer
30/01/23	PRICE SENSITIVE	265.45KB	Share
IPD ImpediMed Announces Appointment of Managing Director and CEO
29/11/22	PRICE SENSITIVE	223.25KB	Share
IPD ImpediMed Announces Management Reorganisation
22/11/22	PRICE SENSITIVE	277.81KB	Share
IPD AstraZeneca Further Extends Clinical Trial Contract
09/11/22	PRICE SENSITIVE	266.76KB	Share
IPD Appendix 4C & Quarterly Activities Report - Sep-22 Qtr
19/10/22	PRICE SENSITIVE	1.44MB	Share
IPD New Corporate Oncology Account with GenesisCare
04/10/22	PRICE SENSITIVE	91.79KB	Share
IPD 2022 Annual Report & Annual General Meeting Date
29/08/22	PRICE SENSITIVE	5.22MB	Share
IPD Appendix 4E
29/08/22	PRICE SENSITIVE	193.36KB	Share
IPD Appendix 4C & Quarterly Activities Report - Jun-2022 Qtr
28/07/22	PRICE SENSITIVE	1.15MB	Share
IPD ImpediMed CEO Announces Departure
26/07/22	PRICE SENSITIVE	133.66KB	Share
IPD Lymphoedema Risk Factors Paper Published
11/07/22	PRICE SENSITIVE	253.37KB	Share
IPD Appendix 4C & Quarterly Activities Report
28/04/22	PRICE SENSITIVE	6.39MB	Share
IPD AstraZeneca extends and increases Renal Contract
18/03/22	PRICE SENSITIVE	268.95KB	Share
IPD S&P DJI Announces March 2022 Quarterly Rebalance
04/03/22	PRICE SENSITIVE	175.5KB	Share
IPD Appendix 4D and Interim Financial Report
25/02/22	PRICE SENSITIVE	2.45MB	Share
IPD ImpediMed Announces End Stage Renal Disease Trial Agreement
11/02/22	PRICE SENSITIVE	272.39KB	Share
IPD PREVENT Trial Peer-Reviewed and Published
01/02/22	PRICE SENSITIVE	107.49KB	Share
IPD Appendix 4C & Quarterly Activities Report
31/01/22	PRICE SENSITIVE	1.37MB	Share
IPD Share Purchase Plan Successfully Completed
18/11/21	PRICE SENSITIVE	319.82KB	Share
IPD 2021 Annual General Meeting - Chairman's Address
10/11/21	PRICE SENSITIVE	363.62KB	Share
IPD AGM Presentation - November 2021
10/11/21	PRICE SENSITIVE	11.58MB	Share
IPD AstraZeneca extends and increases HF & Renal Contract
04/11/21	PRICE SENSITIVE	273.37KB	Share
IPD Share Purchase Plan Offer Booklet
03/11/21	PRICE SENSITIVE	270.02KB	Share
IPD ImpediMed's Share Purchase Plan Opens
03/11/21	PRICE SENSITIVE	325.18KB	Share
IPD Appendix 4C & Quarterly Activities Report
28/10/21	PRICE SENSITIVE	432.8KB	Share
IPD Capital Raising Presentation
27/10/21	PRICE SENSITIVE	2.4MB	Share
IPD ImpediMed Completes A$35 Million Institutional Placement
27/10/21	PRICE SENSITIVE	422.8KB	Share
IPD Trading Halt
25/10/21	PRICE SENSITIVE	278.73KB	Share
IPD PREVENT Trial Successful, Statistically Significant Results
19/10/21	PRICE SENSITIVE	263.77KB	Share
IPD Trading Halt
19/10/21	PRICE SENSITIVE	283.73KB	Share
IPD New Corporate Oncology Account with Icon Group
30/09/21	PRICE SENSITIVE	264.67KB	Share
IPD SOZO Heart Failure Program Initiated at AdvocateAuroraHealth
27/09/21	PRICE SENSITIVE	257.92KB	Share
IPD HFSA Abstracts Demonstrate Utility of SOZO for HF Patients
13/09/21	PRICE SENSITIVE	271.69KB	Share
IPD Appendix 4E
25/08/21	PRICE SENSITIVE	235.99KB	Share
IPD Receipt of $1.8 Million R&D Tax Incentive Refund
24/08/21	PRICE SENSITIVE	247.96KB	Share
IPD FDA Grants Breakthrough Device Designation for Renal Failure
23/08/21	PRICE SENSITIVE	277.41KB	Share
IPD Appendix 4C & Quarterly Activities Report
27/07/21	PRICE SENSITIVE	1.13MB	Share
IPD Official Release of SOZO Version 4.0 Software
25/05/21	PRICE SENSITIVE	538.51KB	Share
IPD ACC Abstract Demonstrates Potential of SOZO in Heart Failure
04/05/21	PRICE SENSITIVE	286.59KB	Share
IPD Appendix 4C - Quarter ended 31 March 2021
28/04/21	PRICE SENSITIVE	1.4MB	Share
IPD FDA Clearance for SOZO Heart Failure Index
22/04/21	PRICE SENSITIVE	424.71KB	Share
IPD SOZO Clinical Utility in Heart Failure Published
08/04/21	PRICE SENSITIVE	363.68KB	Share
IPD Option Exercise and Preliminary Q3 FY21 Cashflow Results
07/04/21	PRICE SENSITIVE	281.79KB	Share
IPD ImpediMed Achieves Milestone 200,000 SOZO Patient Tests
04/03/21	PRICE SENSITIVE	256.58KB	Share
IPD Appendix 4D - Half-Year Results Ended 31 December 2020
22/02/21	PRICE SENSITIVE	2.65MB	Share
IPD American College of Cardiology Accepts SOZO HF Abstract
12/02/21	PRICE SENSITIVE	271.64KB	Share
IPD Appendix 4C - Quarter ended 31 December 2020
28/01/21	PRICE SENSITIVE	1.09MB	Share
IPD PREVENT Trial Finishes, Final Patient Completes Follow-up
11/01/21	PRICE SENSITIVE	263.47KB	Share
IPD Option Exercise and Preliminary Quarterly Cash Flow Results
07/01/21	PRICE SENSITIVE	267.43KB	Share
IPD Meta-Analysis-BIS L-Dex Statistically Significant Reduction
30/11/20	PRICE SENSITIVE	309.44KB	Share
IPD ImpediMed Secures First Commercial Heart Failure Sales
18/11/20	PRICE SENSITIVE	280.47KB	Share
IPD AstraZeneca Selects SOZO for Second Large Renal Trial
09/11/20	PRICE SENSITIVE	268.31KB	Share
IPD Landmark Radiation Manuscript Supports L-Dex Use
29/10/20	PRICE SENSITIVE	285.73KB	Share

REFRESH

1 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 4.4¢		Change -0.001(2.22%)		Mkt cap ! $89.31M

Open	High	Low	Value	Volume
4.4¢	4.4¢	4.3¢	$176.4K	4.014M

Buyers (Bids)

No.	Vol.	Price($)
1	60000	4.3¢

Sellers (Offers)

Price($)	Vol.	No.
4.4¢	185799	1

View Market Depth

No.	Vol.	Price($)
1	60000	0.043
1	25000	0.042
3	538792	0.041
8	474875	0.040
5	235450	0.039

Price($)	Vol.	No.
0.044	185799	1
0.045	914690	4
0.046	118838	1
0.047	100000	1
0.050	70000	2

Last trade - 13.14pm 12/08/2025 (20 minute delay)

IPD (ASX) Chart

IMPEDIMED LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available